MX1 and central nervous system cancer: Since the presence of CDR3-2 was associated with long-term survival in this cohort as well as in another peptide vaccine trial on gliomas (33), we reasoned that the negative impact of MxA expression on CDR3-2 presence could be related to its inverse correlation with patient survival time.